Anton Rx Report

Lo and behold…… the FDA approved yet another biosimilar to Filgrastim.This follow-on product joins two previously approved biosimilars to Neupogen and was christened Releuko (filgrastim-ayow)

Only the second and third tier specialty pharmacies are crying in their beers last week. It comes on the heels of the FTC Commission’s deadlocked

Last week the FDA approved a new oral therapy, Pyrukynd (mitapivat) from Agios Pharma, to treat hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

Last week we sent you a review of an article detailing the creation of a network of alternate site infusion providers by AscellaHealth. On Friday

Payers have been struggling for years to move infusion site of care services out of higher cost hospital outpatient administration to alternate sites….. community physician

Is it the new ‘must-have’ in specialty pharmacy?So it would appear……it’s an accreditation in Rare Disease Pharmacy. A couple of years ago it was bragging

Curiouser and curiouser….. There was a time when PBMs condemned the use of Rx discount coupons saying that doing so upsets the delicate balance of

We are always on the hunt for stories and events that can be impactful on the specialty pharmacy segment. The story below recently crossed out

Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely

The FDA just approved not ONE, but TWO therapies in the already crowded immunology category. The two include a new NDA for Cibinqo (abrocitinib) from Pfizer and an expanded indication for